Vtv Therapeutics logo

Vtv Therapeutics Share Price Today

(NASDAQ: VTVT)

Vtv Therapeutics share price is $21.71 & ₹1,884.19 as on 15 Feb 2025, 2.30 'hrs' IST

$21.71

0.5

(2.38%)

Market is closed - opens 8 PM, 18 Feb 2025

View live Vtv Therapeutics share price in Dollar and Rupees. Guide to invest in Vtv Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Vtv Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Vtv Therapeutics share price movements

  • Today's Low: $19.55
    Today's High: $22.30

    Day's Volatility :12.33%

  • 52 Weeks Low: $8.10
    52 Weeks High: $30.99

    52 Weeks Volatility :73.86%

Vtv Therapeutics (VTVT) Returns

PeriodVtv Therapeutics IncIndex (Russel 2000)
3 Months
25.44%
0.0%
6 Months
36.77%
0.0%
1 Year
120.21%
0.0%
3 Years
-28.86%
-12.5%

Vtv Therapeutics (VTVT) Key Statistics

in dollars & INR

Previous Close
$21.2
Open
$20.33
Today's High
$22.3
Today's Low
$19.55
Market Capitalization
$45.9M
Today's Volume
$9.6K
52 Week High
$30.99
52 Week Low
$8.1
Revenue TTM
$1000.0K
EBITDA
$-22.8M
Earnings Per Share (EPS)
$-4.37
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-362.13%

How to invest in Vtv Therapeutics Stock (VTVT) from India?

It is very easy for Indian residents to invest directly in Vtv Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Vtv Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Vtv Therapeutics or VTVT on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Vtv Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Vtv Therapeutics shares which would translate to 0.040 fractional shares of Vtv Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Vtv Therapeutics, in just a few clicks!

Returns in Vtv Therapeutics (VTVT) for Indian investors in Rupees

The Vtv Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Vtv Therapeutics investment value today

Current value as on today

₹2,29,973

Returns

₹1,29,973

(+129.97%)

Returns from Vtv Therapeutics Stock

₹1,25,441 (+125.44%)

Dollar Returns

₹4,532 (+4.53%)

Indian investors sentiment towards Vtv Therapeutics (VTVT)

-14%

Period: Jan 15, 2025 to Feb 14, 2025. Change in 30 Days versus previous period

Search interest for Vtv Therapeutics Stock from India on INDmoney has decreased by -14% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Vtv Therapeutics

  • Samsara BioCapital, LLC

    7.92%

  • FMR Inc

    6.82%

  • Baker Bros Advisors LP

    3.73%

  • Vanguard Group Inc

    1.59%

  • Geode Capital Management, LLC

    0.39%

  • BlackRock Inc

    0.18%

Analyst Recommendation on Vtv Therapeutics

Buy

    85%Buy

    14%Hold

    0%Sell

Based on 7 Wall street analysts offering stock ratings for Vtv Therapeutics(by analysts ranked 0 to 5 stars)

Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
0
0
0

Analyst Forecast on Vtv Therapeutics Stock (VTVT)

What analysts predicted

Upside of 61.22%

Target:

$35.00

Current:

$21.71

Insights on Vtv Therapeutics Stock (Ticker Symbol: VTVT)

  • Price Movement

    In the last 7 days, VTVT stock has moved up by 18.6%
  • VTVT vs VRTX (3 yr)

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 78.2% return, outperforming this stock by 101.4%

Vtv Therapeutics Technicals Summary

Sell

Neutral

Buy

Vtv Therapeutics is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Vtv Therapeutics (VTVT) Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Vtv Therapeutics Inc logo
50.94%
36.77%
120.21%
-28.86%
-80.59%
Biontech Se logo
8.01%
36.53%
33.94%
-25.81%
289.28%
Regeneron Pharmaceuticals, Inc. logo
-4.15%
-43.66%
-28.88%
6.87%
69.56%
Vertex Pharmaceuticals Incorporated logo
9.03%
-5.22%
9.56%
96.2%
88.09%
Alnylam Pharmaceuticals, Inc. logo
5.53%
-3.49%
80.2%
72.81%
105.85%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Vtv Therapeutics Inc logo
NA
NA
0.0
0.0
-3.62
-0.41
NA
-11.84
Biontech Se logo
160.8
NA
0.04
-3.29
-0.02
-0.01
NA
79.73
Regeneron Pharmaceuticals, Inc. logo
17.32
17.32
0.98
43.2
0.17
0.07
NA
272.04
Vertex Pharmaceuticals Incorporated logo
32.84
NA
1.19
18.18
-0.03
0.12
NA
60.65
Alnylam Pharmaceuticals, Inc. logo
NA
NA
-0.49
-0.18
-15.01
-0.03
NA
0.25
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Vtv Therapeutics Inc logo
Buy
$45.9M
-80.59%
NA
0.0%
Biontech Se logo
Buy
$27.5B
289.28%
160.8
-15.36%
Regeneron Pharmaceuticals, Inc. logo
Buy
$72.6B
69.56%
17.32
33.61%
Vertex Pharmaceuticals Incorporated logo
Buy
$116.9B
88.09%
32.84
-4.51%
Alnylam Pharmaceuticals, Inc. logo
Buy
$34.3B
105.85%
NA
-15.86%

About Vtv Therapeutics

vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2"related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Group LLC.
Organization
Vtv Therapeutics
Employees
16
CEO
Mr. Paul J. Sekhri M.Sc.
Industry
Health Technology

Management People of Vtv Therapeutics

NameTitle
Mr. Paul J. Sekhri M.Sc.
CEO, President & Chairman of the Board
Mr. Steven Tuch M.B.A.
Executive VP & CFO
Dr. Carmen Valcarce Ph.D.
Chief Scientific Officer & Executive VP
Ms. Elizabeth M. Keiley
Executive VP & General Counsel
Mr. Richard S. Nelson
Executive VP of Corporate Development & Director
Dr. Thomas Strack M.D., Ph.D.
Chief Medical Officer

Important FAQs about investing in VTVT Stock from India :

What is Vtv Therapeutics share price today?

Vtv Therapeutics share price today stands at $21.71, Open: $20.33 ; Previous Close: $21.20 ; High: $22.30 ; Low: $19.55 ; 52 Week High: $30.99 ; 52 Week Low: $8.10.

The stock opens at $20.33, after a previous close of $21.20. The stock reached a daily high of $22.30 and a low of $19.55, with a 52-week high of $30.99 and a 52-week low of $8.10.

Can Indians buy Vtv Therapeutics shares?

Yes, Indians can invest in the Vtv Therapeutics (VTVT) from India.

With INDmoney, you can buy Vtv Therapeutics at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Vtv Therapeutics at zero transaction cost.

How can I buy Vtv Therapeutics shares from India?

It is very easy to buy Vtv Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Vtv Therapeutics (VTVT) be purchased?

Yes, you can buy fractional shares of Vtv Therapeutics with INDmoney app.

What are the documents required to start investing in Vtv Therapeutics stocks?

To start investing in Vtv Therapeutics, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Vtv Therapeutics Stock (VTVT)?

Today’s highest price of Vtv Therapeutics (VTVT) is $22.30.

Today’s lowest price of Vtv Therapeutics (VTVT) is $19.55.

What is today's market capitalisation of Vtv Therapeutics?

Today's market capitalisation of Vtv Therapeutics VTVT is 45.9M

What is the 52 Week High and Low Range of Vtv Therapeutics Stock (VTVT)?

  • 52 Week High

    $30.99

  • 52 Week Low

    $8.10

What are the historical returns of Vtv Therapeutics (VTVT)?

  • 1 Month Returns

    50.94%

  • 3 Months Returns

    36.77%

  • 1 Year Returns

    120.21%

  • 5 Years Returns

    -80.59%

Who is the Chief Executive Officer (CEO) of Vtv Therapeutics ?

Mr. Paul J. Sekhri M.Sc. is the current Chief Executive Officer (CEO) of Vtv Therapeutics.